eTheRNA immunotherapies Company

eTheRNA said March 24 that it has started preclinical development of an mRNA vaccine against SARS-CoV-2 that is intended primarily for high-risk populations such as healthcare workers and families of confirmed cases. It is also designed to be protective against future variations of the virus by targeting conserved epitopes from the whole CoV-2 genome.

eTheRNA said it has formed a consortium with EpiVax, Nexelis, REPROCELL and CEV to develop the vaccine and help accelerate progress towards clinical trials; patient enrolment is expected in early 2021. Chinese partners may join the consortium “in due course,” the company added. The consortium’s approach selects conserved epitopes from the whole viral genome to create a vaccine that mounts a strong T cell-based response against these epitopes, which the partners reason offers a better chance to overcome viral variability.
Technology: COVID
Industry: Vaccine/Drug
Headquarters: Belgium
Founded Date: N/A
Employees Number: N/A
Funding Status: N/A

Visit Website
Register and Claim Ownership